High Affinity S-Adenosylmethionine Plasma Membrane Transporter of Leishmania Is a Member of the Folate Biopterin Transporter (FBT) Family*5

Received for publication, February 15, 2010, and in revised form, April 12, 2010 Published, JBC Papers in Press, April 20, 2010, DOI 10.1074/jbc.M110.114520

Larbi Dridi1,2, Amin Ahmed Ouameur1,3, and Marc Ouellette4

From the Centre de Recherche en Infectiologie du CHUL, Université Laval, Québec City, Québec G1V 4G2, Canada

S-Adenosylmethionine (AdoMet) is an important methyl group donor that plays a central role in many essential biochemical processes. The parasite Leishmania can both synthesize and transport AdoMet. Leishmania cells resistant to the antifolate methotrexate due to a rearrangement in folate biopterin transporter (FBT) genes were cross-resistant to sinefungin, an AdoMet analogue. FBT gene rearrangements were also observed in Leishmania major cells selected for sinefungin resistance. One of the rearranged FBT genes corresponded to the main AdoMet transporter (AdoMetT1) of Leishmania as determined by gene transfection and gene inactivation experiments. AdoMetT1 was determined to be a high affinity plasma membrane transporter expressed constitutively throughout the growth phases of the parasite. Leishmania cells selected for resistance or naturally insensitive to sinefungin had lower expression of AdoMetT1. A new function in one carbon metabolism, also a pathway of interest for chemotherapeutic interventions, is described for a novel class of membrane proteins found in diverse organisms.

The parasite Leishmania is distributed globally and causes a variety of clinical symptoms ranging from self-healing cutaneous lesions to visceral infections that are usually fatal if left untreated (1, 2). Current first-line chemotherapy against leishmaniasis relies on a rather limited arsenal of drugs, including pentavalent antimonials, liposomal amphotericin B, or miltefosine (2). These drugs are associated with side effects, high costs, and drug resistance, and therefore, the search for new drugs and targets to control this parasite is warranted (3, 4).

S-Adenosylmethionine (AdoMet or SAM)5 is an important biological sulfonium compound recognized as the universal methyl donor for methylation of lipids, proteins, nucleic acids, and xenobiotics in living cells (5). AdoMet is also a donor of propylamine groups for the synthesis of polyamines and participates in the reverse trans-sulfuration pathway where AdoMet is converted into cysteine and glutathione and in Leishmania in the spermidine-glutathione conjugate trypanothione (6, 7). AdoMet is also used as a source of methylene groups, amino groups, and ribosyl groups in the synthesis of fatty acids, biotin, and the modified nucleoside epoxysouqueusine of tRNAs (reviewed in Ref. 8).

Most cells are capable of synthesizing AdoMet from l-methionine and ATP, in a process requiring the enzyme methionine adenosyltransferase (MAT). The gene coding for this enzyme is present in most sequenced organisms (reviewed in Ref. 9). However, in some Rickettsia strains, the MAT gene is inactivated by a mutation (10), and in the fungus Pneumocystis carinii, no MAT activity has been detected (11). These organisms have the rare distinction of meeting their AdoMet needs by importing it (12). The Rickettsia transporter is part of the drug/metabolite transporter superfamily (10), and the identity of the Pneumocystis transporter is not known. Transport of AdoMet across the plasma membrane does not occur to a significant extent in mammalian cells, but transport of AdoMet is essential in several organelles. For example, the yeast (13) and human (14) mitochondrial AdoMet transporters and the Arabidopsis AdoMet plastid (and mitochondria) transporter (15, 16) have been functionally characterized. They belong to the mitochondrial carrier protein family (MCF), a class of protein mediating the transport of various substrates (reviewed in Ref. 17).

Other organisms, notably fungus and protozoa, have the ability to both synthesize and transport AdoMet. The only eukaryotic plasma membrane AdoMet transporter characterized to date is the Saccharomyces cerevisiae SAM3 protein (18) belonging to the amino acid permease superfamily. Although SAM3 transports AdoMet, it also transports polyamines with high affinity (19). Sinefungin (SNF) is an analogue of AdoMet with antimicrobial activity, and yeast SNF-resistant mutants were shown to have loss-of-function mutations in SAM3 (20). In the protozoan parasites Leishmania (21) and Trypanosoma brucei (22), SNF and AdoMef were shown, on the basis of substrate competition transport experiments, to share a common transporter protein. We report here the cloning and functional characterization of the unique high affinity AdoMef transporter of carrier protein family; MTX, methotrexate; SNF, sinefungin; FA, folic acid; UTR, untranslated region.

© 2010 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
**S-Adenosylmethionine Transporter of Leishmania**

*Leishmania* and show that it belongs to the FBT family, a class of proteins present in diverse organisms.

**MATERIALS AND METHODS**

**Cell Lines and Culture Conditions—Leishmania cells** (*Leishmania infantum MHOM/MA/67/ITMAP-263, L. infantum IPCM5, Leishmania tarentolae, Leishmania major Friedlin, and L. major LV39*) were grown in SDM-79 medium supplemented with 10% heat-inactivated fetal bovine serum, 5 μg/ml hemin, and, when required, 10 μM biotin (Sigma). The *L. tarentolae* methotrexate (MTX)-resistant mutant TarMTX1000.6 was described previously (23). The *L. tarentolae* and *L. major* LV39 SNF-resistant mutants, named TarSNF8 and LV39SNF4000.4, respectively, were selected with SNF in a step-by-step manner as described in details for other drugs (24). Cell growth was monitored by measuring the absorbance of culture aliquots at 600 nm in a multwell scanning spectrophotometer. DNA transfection into *Leishmania* promastigotes has been performed as described previously (25).

**AdoMetT1 Gene Transfection and Inactivation**—The *AdoMetT1* gene of *L. infantum* (*Lin10_V3.0370*) was amplified from genomic DNA using primer pairs 1–2 and 3–4 (see supplemental Table S1). The PCR fragment was first ligated into the pGEM T-easy vector (Invitrogen), digested with the appropriate restriction enzymes, and cloned into the relevant restriction sites within the *Leishmania* expression vectors pSP72αHYGα (26) and pSPαNEOα-GFP (27).

The *L. infantum* *AdoMetT1* null mutant was obtained by targeted gene replacement. The *AdoMetT1* inactivation cassettes were generated using a PCR fusion-based strategy as described previously (28). Primers used to generate the inactivation cassettes are listed in supplemental Table S1. Briefly, the NEO inactivation cassette was generated by using the primer pairs 5–6 and 7–8 to amplify DNA fragments of 730 bp upstream and 680 bp downstream of the *AdoMetT1* gene, respectively. The neomycin phosphotransferase (NEO) gene was amplified from the plasmid pSPαNEOα using primers 9 and 10 and then fused to the upstream and downstream DNA fragments of *AdoMetT1* using PCR. The same strategy was used to generate the ZEO cassette; primer pairs 5–11 and 12–8 were used to amplify the upstream and downstream fragments of *AdoMetT1*, whereas primers 13 and 14 were used to amplify the ZEO gene from the pSPαZEOα vector (29).

**Cellular Transport Assays**—TarMTX1000.6 expressing the AdoMet transporter (*AdoMetT1*) and the folic acid transporter (FT1) were harvested during the mid-logarithmic phase. 10⁸ cells were washed and resuspended in folate-deficient medium fDMEL or AdoMet-deficient medium with 115 nM [3H]folic acid (43.2 Ci/mmol) or 60 nM [3H]AdoMet (83 Ci/mmol) (Moravek Biochemicals), respectively. Accumulation was measured as described previously (30). Folic acid uptake was normalized to cell number, and the background transport value was removed by subtracting the accumulation value obtained on ice. The transport kinetic parameters *V*<sub>max</sub> and apparent *K*<sub>m</sub> values for AdoMet were measured while using different [3H]AdoMet concentrations (3–3000 nM) during the linear phase of accumulation (5 min). Transport kinetic parameters were determined by linear regression analysis and Michaelis-Menten analysis.

The transport competition study was performed with 5 × 10⁷ LV39SNF4000.4 cells expressing the AdoMetT1-GFP protein. Briefly, cells were incubated for 10 min in an assay buffer, as described previously (31), containing 50 nM radioactive AdoMet in the presence or absence of various concentrations (100 nM and 1 and 10 μM) of competing molecules. For all transport experiments, the accumulation in cells incubated on ice was subtracted.

**Quantitative Real Time Reverse Transcription-PCR**—Three independent RNA preparations were used for each real time PCR experiment. RNA extractions, cDNA synthesis, and TaqMan quantification of *AdoMetT1* were performed as described previously (27). Primers and Taqman probes are listed in supplemental Table S2. Real time reverse transcription-PCR for the *MAT* gene was performed as described previously (32) using *GAPDH* and actin genes as controls (supplemental Table S2).

**Western Blot Analysis**—Total *Leishmania* proteins (30 μg) were run on 12% polyacrylamide gels and transferred onto nitrocellulose membranes as described previously (33). The blots were blocked overnight in 5% skimmed milk in 1× phosphate-buffered saline (PBS). A monoclonal anti-α-tubulin antibody (Sigma) directed against a conserved amino-terminal peptide of the bovine α-tubulin or an antibody against the green fluorescent protein (GFP) (Invitrogen) was diluted 1:3000 in PBS containing 0.1% Tween 20 (PBS/Tween) and incubated for 1 h with the membranes. The blots were washed three times for 5 min in PBS/Tween and incubated with horseradish peroxidase-conjugated sheep anti-rabbit IgG for GFP or sheep anti-mouse IgG for α-tubulin (Amersham Biosciences) diluted 1:10,000 in PBS/Tween. The blots were washed as above, incubated with ECL Plus chemiluminescent substrate (Amersham Biosciences), and exposed to x-ray films. The polyclonal rabbit MAT antibody was kindly provided by Prof. Balana-Fouce (University of Leon, Spain) and was used as described previously (34).

**Southern Analysis**—*Leishmania* total DNAs were isolated using DNAzol reagent as recommended by the manufacturer (Invitrogen). For Southern blots, genomic DNAs were digested with PvuI to monitor rearrangement events of the FBT family and with PstI for analysis of the *AdoMetT1*-null mutant. Southern blots, hybridizations, and washes were performed following standard protocols (35), and all probes were obtained by PCR. The FBT gene family was studied with a DNA probe spanning the conserved coding sequences of the *FBT* genes (27), and *AdoMetT1* allele replacement was confirmed by using a probe targeting the 3′-UTR of *AdoMetT1*.

**Fluorescence Microscopy**—Live parasites were mounted under poly-L-lysine-coated coverslips. Coverslips were sealed with nail varnish and air-dried for 15 min. Bright field and fluorescence images were taken using a Nikon Eclipse TE300 inverted microscope with a Photometrics coolSNAPFx camera. Visualization of the GFP fluorophore was achieved using a 460/500-nm excitation filter and 510/560-nm emission filter with a 100× objective. The images were processed using the Image-Pro Plus software (version 5.0).
RESULTS

Leishmania Methotrexate-resistant Mutant Is Cross-resistant to Sinefungin—Folic acid (FA) and AdoMet are the one-carbon metabolic donors in cells, and previous reports have demonstrated that AdoMet metabolism is potentially changed in Leishmania cells resistant to the FA analogue MTX (29, 36). Indeed, the L. tarentolae MTX1000.6 mutant is resistant to MTX (Fig. 1A) due to decreased accumulation of MTX or FA (see Fig. 2A and data not shown). This reduced accumulation is due to gene deletion and rearrangements of the FBT transporter FT1 (37). Surprisingly, this mutant was also found to be cross-resistant to the AdoMet analogue SNF (Fig. 1B). This intriguing observation led us to further investigate SNF susceptibility in Leishmania cells.

L. tarentolae and L. major wild-type cells were sensitive to MTX (Fig. 1A). However, although L. tarentolae and L. major LV39 were sensitive to SNF, L. major Friedlin was intrinsically resistant to it (Fig. 1B and Table 1). Similarly, whereas the L. infantum 263 strain was highly sensitive to SNF, the genome strain L. infantum JPCM5 was intrinsically resistant (Table 1). L. tarentolae and L. major LV39 cells were selected in a step-by-step fashion for resistance to SNF, and these cells were indeed resistant to SNF (Fig. 1B) but not cross-resistant to MTX (Fig. 1A).

Resistance to MTX in L. tarentolae MTX1000.6 is due to a reduced uptake of the drug (23), which is paralleled by a reduction in the uptake of the analogue FA (Fig. 2A).

| Strains          | IC<sub>50</sub> value of sinefungin | \( K_m \) | \( V_{max} \) |
|------------------|------------------------------------|---------|--------|
| L. infantum MHOM/MA/67/ITMAP-263 | 80 ± 18 | 167 ± 27 | 0.56 ± 0.17 |
| L. infantum JPCM5 | 2000 ± 300 | 180 ± 82 | 0.05 ± 0.01 |
| L. major LV39    | 50 ± 4  | 252 ± 10 | 0.57 ± 0.13 |
| L. major Friedlin| >6000   | 320 ± 7  | 0.03 ± 0.01 |
| LV39SNF4000.4 + AdoMetT1-GFP | 10 ± 2 | 284 ± 72 | 0.58 ± 0.24 |

S-Adenosylmethionine Transporter of Leishmania

**FIGURE 1.** Sensitivity of Leishmania cells to methotrexate and sinefungin. Leishmania cells were incubated in SDM medium with varying concentrations of methotrexate (A) and sinefungin (B), and their growth was monitored at 72 h by measuring the absorbance at 600 nm. F, L. tarentolae wild type; C, L. tarentolae MTX1000.6; A, TarSNF.8; D, L. major Friedlin; E, L. major LV39; F, LV39SNF4000.4. The average of triplicate measurements is shown.

**FIGURE 2.** Folic acid and S-adenosylmethionine accumulation in Leishmania cells. The accumulation of 115 nM [3H]folic acid (A) and 60 nM S-[3H]adenosylmethionine (B) was measured in Leishmania cells. F, L. tarentolae wild type; C, L. tarentolae MTX1000.6; A, TarSNF.8; D, L. major Friedlin; E, L. major LV39; F, LV39SNF4000.4. The average of triplicate measurements is shown.
S-Adenosylmethionine Transporter of Leishmania

Accordingly, we tested whether cross-resistance to SNF in *L. tarentolae* MTX1000.6 correlated with a reduced accumulation of AdoMet and whether cells intrinsically resistant (*L. major* Friedlin or *L. infantum* JCPM5) or made resistant to SNF also exhibited a reduced accumulation of AdoMet. Wild-type *L. tarentolae* and *L. major* LV39 accumulated AdoMet, but all strains not susceptible to SNF, regardless of whether resistance was intrinsic or acquired, did not (Fig. 2B).

**AdoMet Transporter Is a Member of the FBT Family—**The *L. tarentolae* MTX1000.6 mutant was resistant to both MTX and SNF (Fig. 1), a phenotype accompanied by a reduced accumulation of FA and AdoMet (Fig. 2). Because there are rearrangements of the FBT gene family in this mutant (30), we hypothesized that the lack of AdoMet transport in this mutant could be correlated with FBT gene rearrangements. This was also investigated in *L. tarentolae* and *L. major* cells made resistant to SNF where the genomic DNAs of the mutants were digested with PvuI and hybridized to a FBT probe. There were no clear rearrangements in the *L. tarentolae*-resistant mutant SNF8 (results not shown). However, there was a clear rearrangement of some of the FBT family members in the *L. major*-resistant LV39SNF4000.4 mutant compared with its parental wild-type SNF-sensitive isolate (Fig. 3A). According to the published genome sequence of *L. major*, the high molecular weight (>12 kb) rearranged band most likely encodes three FBT genes (*LmjF10.0350, LmjF10.0360*, and *LmjF10.0370*). The corresponding *L. infantum* orthologues *LinJ10_V3.0.0350, LinJ10_V3.0.0360*, and *LinJ10_V3.0.0380* were cloned into expression vectors and transfected in the SNF-resistant cells *L. tarentolae* MTX1000.6 and LV39SNF4000.4. Cells transfected with *LinJ10_V3.0.0370* but not the other two constructs became highly sensitive to SNF (Fig. 3B and results not shown). This transporter clearly did not correspond to FT1 (*LinJ10_V3.0.0400*). Indeed, *L. tarentolae* MTX1000.6 transfected with FT1 was still highly resistant to SNF (Fig. 3B) but became highly sensitive to MTX (Fig. 3C). *L. tarentolae* MTX1000.6 transfected with *LinJ10_V3.0.0370* remained resistant to MTX (Fig. 3C). Because *LinJ10_V3.0.0370* sequence of *LinJ10_V3.0.0370* was thus renamed AdoMetT1. *L. tarentolae* MTX1000.6 or
SNF8 cells did not accumulate AdoMet, but the same cells transfected with AdoMetT1 were capable of transporting AdoMet (Fig. 4C). However, L. tarentolae MTX1000.6 cells transfected with AdoMetT1 did not transport FA, whereas the same cells transfected with FT1 did (Fig. 4D).

To further link AdoMetT1 to AdoMet transport, we attempted to generate an L. infantum AdoMetT1 null mutant. Two replacement cassettes were made, which allowed AdoMetT1 to be replaced by either the NEO or ZEO genes (Fig. 5A). These constructs were transfected independently in wild-type cells and selected for resistance to either G418 or Zeocin. Leishmania is diploid, and when its DNA is digested with PstI and hybridized to a 3′-UTR AdoMetT1 probe, the resulting hybridized fragment should be 6.2 kb in length (Fig. 5A). Integration of either the NEO or ZEO cassette and digesting with PstI and hybridizing to the same probe should lead to fragments of 5.5 and 5.7 kb, respectively (Fig. 5A). Analysis of wild-type cells and AdoMetT1/NEO or AdoMetT1/ZEO transfectants digested with PstI and hybridized with the 3′-UTR probe were completely consistent with the above scenario (Fig. 5B, lanes 1–3). The ZEO cassette was introduced in an AdoMetT1/NEO clone, and molecular analysis of the resulting transfectant was consistent with the generation of an AdoMetT1 null mutant. Indeed, the 6.2-kb band corresponding to the intact AdoMetT1 gene disappeared, whereas bands corresponding to the integration of NEO and ZEO inactivation cassettes were observed (Fig. 5B, lane 4). The L. infantum-263 wild-type cells were sensitive to SNF (Fig. 5C) and accumulated AdoMet (Fig. 5D). However, the AdoMetT1/NEO cells exhibited intermediate sensitivity to SNF (Fig. 5C) and accumulated less AdoMet (Fig. 5, C and D). The NEO/ZEO AdoMetT1 null mutant was insensitive to SNF and did not accumulate any measurable AdoMet (Fig. 5, C and D). We confirmed that these phenotypes were indeed due to the lack of AdoMetT1, because transfection of an episomal add-back construct encoding AdoMetT1 into the null mutant rescued both the susceptibility to SNF and the transport of AdoMet (Fig. 5, C and D).

AdoMetT1 Is a Specific High Affinity AdoMet Transporter Expressed Constitutively—The kinetic properties of AdoMetT1 were studied, and the $K_m$ value was determined to be in the 150–300 nM range for both L. major and L. infantum (Table 1). The $V_{max}$ values was calculated to be at least 10 times higher in cells sensitive to SNF compared with cells intrinsically less susceptible to SNF (Table 1). We tested whether AdoMetT1 was specific for AdoMet by challenging the accumulation of $[^3H]$AdoMet with related substrates. AdoMet itself and SNF were shown to inhibit the accumulation of the radioactive substrate but neither adenine nor adenine, cysteine, ornithine, methionine, or homocysteine competed with AdoMet uptake (Fig. 6). Only $S$-adenosylhomocysteine, at a high concentration, was able to compete with the accumulation of AdoMet (Fig. 6).

The transport of FA mediated by the FBT member FT1 is stage-regulated in Leishmania, with maximal activity in the logarithmic phase of growth (38). Indeed, during the progression of the parasite toward its stationary phase, there is increased FT1 protein degradation (37). We tested whether AdoMetT1 and AdoMet transport were under similar stage regulation. AdoMet transport increased during log phase, but in contrast to FA, it remained constant during the stationary phase (Fig. 7). Consistent with these results, AdoMetT1-GFP fusions were not degraded in the stationary phase of growth with the fusion protein migrating at the expected 100-kDa size. Moreover, AdoMetT1-GFP was at the level of the plasma membrane in stationary cells as deduced from fluorescence microscopy (Fig. 7). The same lack of growth stage regulation was observed for both L. major and L. infantum (Fig. 7 and results not shown).

Molecular Basis for Intrinsic and Acquired Resistance to Sinefungin—L. major Friedlin and L. infantum IPCM5 were intrinsically resistant to SNF, whereas L. major LV39 and L. infantum-263 were sensitive to it. This correlates with a decrease in the transport of AdoMet (Fig. 2 and Table 1) and most likely SNF (Fig. 6). We sequenced the AdoMetT1 gene in cells incapable of AdoMet transport, and we found that
the coding sequence of the gene was identical to the published sequence. We next measured the expression of AdoMetT1 by quantitative reverse transcription-PCR and found that its expression was 20 times higher in L. major LV39 compared with L. major Friedlin (Fig. 8A). The expression of the MAT and FT1 genes was similar in the two L. major strains (Fig. 8A). The expression of AdoMetT1 was also higher (3-fold) in the AdoMet-transporting strain L. infantum-263 compared with L. infantum JPCM5 (Fig. 8B). The expression of the MAT gene was similar in the two L. infantum strains, but the FT1 gene was also expressed at higher level in L. infantum-263 (Fig. 8B). Incidentally, we found that L. infantum-263 was more sensitive to MTX compared with strain JPCM5 (results not shown), an observation that could be attributed to the difference in FT1 expression.

We also sequenced the AdoMetT1 open reading frame in the SNF-resistant mutant LV39SNF4000.4, and we compared that sequence with that of the L. major LV39 strain and found that they were identical (results not shown). However, the expression of AdoMetT1 was down-regulated 11-fold in cells in which resistance was induced compared with the wild-type cells as determined by quantitative reverse transcription-PCR (Fig. 8C). The reduction in AdoMetT1 expression correlated with a decrease of the \( V_{\text{max}} \) value in the transport of AdoMet (Table 1). Unfortunately, this quantitative reverse transcription-PCR assay could not be applied to SNF-sensitive and -resistant L. tarentolae, possibly because the sequence of AdoMetT1 in this species was too divergent.

**DISCUSSION**

The first indirect evidence for an AdoMet transporter in *Leishmania* came from the observation that SNF, an AdoMet analogue, had inhibitory effects against the parasite (39). Biochemical evidence was later obtained that demon-
strated both the capacity of *Leishmania* to accumulate AdoMet (40) and that AdoMet and SNF shared the same uptake system (21). Our study now identifies the high affinity AdoMet transporter in *Leishmania* as AdoMetT1, a membrane protein in the FBT family. The FBT family is a novel class of membrane proteins, which is part of the major facilitator superfamily (41, 42). They were first characterized in *Leishmania* (30, 43) but are present also in other kinetoplastid parasites (27) or in Apicomplexa parasites such as malaria and *Toxoplasma* (44, 45), in plants, and in cyanobacteria (46). So far, the only function attributed to these proteins was the transport of unconjugated (47, 48) or conjugated pterins such as FA (30, 37, 46, 49). With 14 members, *Leishmania* has the largest number of FBTs, but the function of only three members, BT1, FT1, and FT5 is known. The remaining 11 *Leishmania* proteins in the FBT family are unlikely to correspond to plasma membrane FA transporters (27). The function of a fourth member of the FBT family, namely AdoMetT1, has now been revealed. As such, it would be of interest to investigate the role of AdoMetT1 homologues in other organisms containing FBTs, to determine whether they too can transport AdoMet. This would be particularly important in *Trypanosoma brucei*, the parasite responsible for sleeping sickness. Indeed, based on the unique biochemical properties of AdoMet transport in *T. brucei*, it was suggested that the transporter could serve as a novel route for the delivery of drugs (50). *T. brucei* has seven FBT homologues (27) and determining if any of these function in AdoMet transport would be an important endeavor. In particular, several S-adenosylmethionine decarboxylase inhibitors are being developed against parasites (51–53), and some of these may enter through an AdoMet transporter. Sinefungin, but none of the individual AdoMet building blocks, can inhibit AdoMet uptake in *T. brucei* (22), and this is consistent with our observations for *Leishmania* AdoMetT1 (Fig. 6). The *Km* value of the *T. brucei* AdoMet transport was reported to be in the millimolar range (54) indicating a lower affinity than *Leishmania* AdoMetT1, which is in the nanomolar range (Table 1).

FBTs have also been described in plants with nine members in *Arabidopsis*, one of which transports FA (46). The plastid AdoMet transporter, named SAMT1, is not a member of the FBT family but is part of the MCF (15, 16). MCF proteins are also responsible for AdoMet transport in yeast (13) and human mitochondria (14). Interestingly, *Leishmania* also encodes MCF proteins, one of which appears to be an orthologue of the mitochondrial AdoMet transporter (55). Disruption of the *Arabidopsis* SAMT1 gene led to a severe growth defect, but because the plants remained viable, it was suggested that other proteins could be implicated in AdoMet transport (15). It is possible that one of the plant FBTs could be involved as a secondary organelar AdoMet transporter.

The *Leishmania* AdoMetT1 transports AdoMet specifically in the low nanomolar range, whereas FT1, also a FBT member, exclusively transports FA in the nanomolar range (37, 43). Other FBTs highly homologous to either AdoMetT1 or FT1 transport neither AdoMet nor FA. Because AdoMetT1 and FT1 are 80% identical (27), it should be possible to find key regions and eventually amino acids involved in substrate specificity. Interestingly, AdoMetT1 and FT1 are regulated very differently at the post-translational level with FT1 being degraded in stationary phase (37), whereas AdoMetT1 is expressed constitutively (Fig. 7). Although the signals implicated in the degradation of FT1 are unknown, the production of AdoMetT1/FT1 fusion proteins could aid in identifying motifs involved in protein degradation in *Leishmania*.

Sinefungin has been found to be active against several *Leishmania* species (39, 56) but also against other parasites, including malaria (57), and the trypanosomes (58). It was suggested to have the potential to serve as a lead compound for a novel antiparasitic drug (59). However, some *Leishmania* strains were found to be intrinsically resistant to SNF (60), a finding supported here with the intrinsic SNF resistance observed in *L. major* Friedlin or *L. infantum* JPCM5 (Table 1). This phenomenon can now be plausibly explained by the defect in AdoMet transport (Fig. 2B), which is also related to lower *AdoMetT1* expression (Fig. 8) and to a reduced *Vmax* for AdoMet transport (Table 1). The disruption of *AdoMetT1* also leads to SNF resistance (Fig. 5). Interestingly, the selection for resistance to SNF in *Leishmania* was also correlated to a decrease in the expression of *AdoMetT1* (Fig. 8). The mechanism by which this happens is not yet clear, but it could be related to the gene rearrangement observed in our study (Fig. 3A). Reduced RNA levels in *Leishmania* are usually due to a decrease in gene copy number (61, 62), although other mechanisms may also occur (63). Interestingly, in the yeast *S. cerevisiae* that also transports AdoMet, resistance to SNF was shown to correlate with loss of function mutations in the AdoMet transporter Sam3 (20).
**S-Adenosylmethionine Transporter of Leishmania**

Although the overexpression of MAT was shown to confer resistance to SNF in *Leishmania* (64), it is not involved in the decreased susceptibility observed here because the expression of MAT was not changed in our resistant cells at either the RNA (Fig. 8C) or protein level (result not shown). The expression of MAT was also not increased in cells with reduced expression of *AdoMetT1* (Fig. 8) or in cells in which *AdoMetT1* was disrupted (results not shown). *Leishmania* strains can be sensitive to SNF in the low nanomolar range (Fig. 1), but several strains demonstrated no intrinsic susceptibility (Table 1) (60) possibly because of lower *AdoMetT1* expression. We could nonetheless envisage using more lipophilic analogues of SNF, which may not require a specific transporter, as novel chemotherapeutic agents against *Leishmania*.

Pneumocystis appears to depend exclusively on AdoMet uptake to meet its AdoMet needs (11), but *Leishmania* can either synthesize it or salvage it from its environment. We have inactivated *AdoMetT1 in L. infantum* (Fig. 5), and the resultant cells were viable, showed no obvious growth defect, and retained the ability to infect macrophages (results not shown). Several organisms use synthesis as their main source of AdoMet, to import AdoMet directly from the environment. It may thus be advantageous, under limiting concentrations of metabolic precursors, to import AdoMet directly from the environment. *Leishmania* is a purine auxotroph with numerous salvage pathways (65), and one could envision that under purine-poor conditions, the uptake of AdoMet could serve as a purine source. Synthesis of AdoMet is energetically expensive because for each molecule of AdoMet synthesized, the three high energy phosphodiester bonds of ATP are hydrolyzed (9). When AdoMet is present in the environment, and under energetic constraint, it may thus be advantageous for the parasite to import AdoMet instead of synthesizing it. The *Leishmania* MAT activity is maximal during logarithmic phase of growth and negligible in the stationary phase (7). If AdoMet is required during other growth phases of the parasite, it could also be useful for the organism to import it to compensate for a reduced rate of synthesis. Although cells without *AdoMetT1* expression (Fig. 8) thrive well under laboratory conditions, it is possible that under specific conditions they may be at a disadvantage or that the expression of the gene is induced. The identification of the AdoMet transporter will now allow the testing of some of these hypotheses in *Leishmania* and also in other organisms.

Acknowledgments—We thank Dr. Jeremy Mottram for the *L. infantum* JPCM5 strain and Dr. Balana-Fouce for the anti-MAT antibody. We also thank Drs. Danielle Légéré, Angana Mukherjee, Philippe Leprohon, and Jennifer Raven for critical reading of the manuscript.

**REFERENCES**

1. Herwaldt, B. L. (1999) *Lancet* **354**, 1191–1199
2. Murray, H. W., Berman, J. D., Davies, C. R., and Saravia, N. G. (2005) *Lancet* **366**, 1561–1577
3. Ouellette, M., Drummelsmith, J., and Papadopoulou, B. (2004) *Drug Resist. Updat.* **7**, 257–266
4. Croft, S. L., Sundar, S., and Fairlamb, A. H. (2006) *Clin. Microbiol. Rev.* **19**, 111–126
5. Lu, S. C., and Mato, J. M. (2008) *J. Gastroenterol. Hepatol.* **23**, 573–577
6. Fairlamb, A. H., and Cerami, A. (1992) *Annu. Rev. Microbiol.* **46**, 695–729
7. Reguera, R. M., Redondo, C. M., Pérez-Pertejo, Y., and Balaña-Fouce, R. (2007) *Mol. Biochem. Parasitol.* **152**, 1–10
8. Fontecave, M., Atta, M., and Mulliez, E. (2004) *Trends Biochem. Sci.* **29**, 243–249
9. Mato, J. M., Corrales, F. J., Lu, S. C., and Avila, M. A. (2002) *FASEB J.* **16**, 15–26
10. Tucker, A. M., Winkler, H. H., Driscoll, L. O., and Wood, D. O. (2003) *J. Bacteriol.* **185**, 3031–3035
11. Meraili, S., Vargas, D., Franklin, M., and Clarkson, A. B., Jr. (2000) *J. Biol. Chem.* **275**, 14958–14963
12. Meraili, S., and Clarkson, A. B., Jr. (2004) *FEMS Microbiol. Lett.* **237**, 179–186
13. Marobbio, C. M., Agrimi, G., Lasorsa, F. M., and Palmieri, F. (2003) *EMBO J.* **22**, 5975–5982
14. Agrimi, G., Di Noia, M. A., Marobbio, C. M., Fiermonte, G., Lasorsa, F. M., and Palmieri, F. (2004) *Biochem. J.* **379**, 183–190
15. Bouvier, F., Linka, N., Isner, J. C., Mutterer, J., Weber, A. P., and Camara, B. (2006) *Plant Cell* **18**, 3088–3105
16. Palmieri, L., Arrigoni, R., Blanco, E., Carrari, F., Zanor, M. I., Studart-Guimaraes, C., Fernie, A. R., and Palmieri, F. (2006) *Plant Physiol.* **142**, 855–865
17. Haferkamp, I. (2007) *FEBS Lett.* **581**, 2375–2379
18. Rouillon, A., Sürdin-Kerjan, Y., and Thomas, D. (1999) *J. Biol. Chem.* **274**, 28096–28105
19. Uemura, T., Kashiwagi, K., and Igarashi, K. (2007) *J. Biol. Chem.* **282**, 7733–7741
20. Zheng, S., Shuman, S., and Schwer, B. (2007) *Nucleic Acids Res.* **35**, 6895–6903
21. Phelouzat, M. A., Basselin, M., Lawrence, F., and Robert-Gero, M. (1995) *Biochem. J.* **305**, 133–137
22. Goldberg, B., Rattendi, D., Lloyd, D., Sufrin, J. R., and Bachci, C. J. (1998) *Biochem. Pharmacol.* **56**, 95–103
23. Papadopoulou, B., Roy, G., and Ouellette, M. (1993) *Nucleic Acids Res.* **21**, 4305–4312
24. Ouellette, M., Fase-Fowler, F., and Borst, P. (1990) *EMBO J.* **9**, 1027–1033
25. Papadopoulou, B., Roy, G., and Ouellette, M. (1992) *EMBO J.* **11**, 3601–3608
26. El Faradi, A., Kündig, C., and Ouellette, M. (2002) *Mol. Biochem. Parasitol.* **124**, 63–71
27. Ouameur, A. A., Giraud, I., Légaré, D., and Ouellette, M. (2008) *Mol. Biochem. Parasitol.* **162**, 155–164
28. Moreira, W., Leblanc, E., and Ouellette, M. (2009) *Free Radic. Biol. Med.* **46**, 367–375
29. Drummelsmith, J., Girard, I., Trudel, N., and Ouellette, M. (2004) *J. Biol. Chem.* **279**, 33273–33280
30. Richard, D., Kündig, C., and Ouellette, M. (2002) *J. Biol. Chem.* **277**, 29460–29467
31. Al-Salahi, M. I., Wallace, L. J., and De Koning, H. P. (2003) *Mol. Pharma- col.* **63**, 814–820
32. Gagnon, D., Foucher, A., Girard, I., and Ouellette, M. (2006) *Mol. Biochem. Parasitol.* **150**, 63–71
33. Foucher, A. L., Papadopoulou, B., and Ouellette, M. (2006) *J. Protozool. Res.* **5**, 1741–1750
34. Reguera, R. M., Balaña-Fouce, R., Pérez-Pertejo, Y., Fernández, F. J., García-Estrada, C., Cubría, C. J., Ordóñez, C., and Ordóñez, D. (2002) *J. Biol. Chem.* **277**, 3158–3167
35. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) *Molecular Cloning A Laboratory Manual*, pp. 9.31–9.62, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
36. Guimond, C., Trudel, N., Brochu, C., Marquis, N., El Faradi, A., Peytavi, R., Briand, G., Richard, D., Messier, N., Papadopoulou, B., Corbeil, J.,
51. Bacchi, C. J., Barker, R. H., Jr., Rodriguez, A., Hirth, B., Rattendi, D., Yarlett, N., Hendrick, C. L., and Sybertz, E. (2009) *Antimicrob. Agents Chemother.* **53**, 3269–3272
52. Hirth, B., Barker, R. H., Jr., Celatka, C. A., Klinger, J. D., Liu, H., Nare, B., Nijjar, A., Phillips, M. A., Sybertz, E., Willert, E. K., and Xiang, Y. (2009) *Bioorg. Med. Chem. Lett.* **19**, 2916–2919
53. Barker, R. H., Jr., Liu, H., Hirth, B., Celatka, C. A., Fitzpatrick, R., Xiang, Y., Willert, E. K., Phillips, M. A., Kaiser, M., Bacchi, C. J., Rodriguez, A., Yarlett, N., Klinger, J. D., and Sybertz, E. (2009) *Antimicrob. Agents Chemother.* **53**, 2052–2058
54. Goldberg, B., Rattendi, D., Lloyd, D., Yarlett, N., and Bacchi, C. J. (1999) *Arch. Biochem. Biophys.* **364**, 13–18
55. Colasante, C., Peña Díaz, P., Clayton, C., and Voncken, F. (2009) *Mol. Biochem. Parasitol.* **167**, 104–117
56. Paolantonacci, P., Lawrence, F., and Robert-Géron, M. (1985) *Antimicrob. Agents Chemother.* **28**, 528–531
57. Trager, W., Tershakovec, M., Chiang, P. K., and Cantoni, G. L. (1980) *Exp. Parasitol.* **50**, 83–89
58. Dube, D. K., Mpimbaza, G., Allison, A. C., Lederer, E., and Rovis, L. (1983) *Ann. J. Trop. Med. Hyg.* **31**, 31–33
59. Nolan, L. L. (1987) *Antimicrob. Agents Chemother.* **31**, 1542–1548
60. Avila, J. L., and Avila, A. (1987) *Mol. Biochem. Parasitol.* **26**, 69–75
61. Ubeda, J. M., Légaré, D., Raymond, F., Ouameur, A. A., Boisvert, S., Rigault, P., Corbeil, J., Tremblay, M. J., Olivier, M., Papadopoulou, B., and Ouellette, M. (2008) *Genome Biol.* **9**, R115
62. Leprohon, P., Légaré, D., Raymond, F., Madore, E., Hardiman, G., Corbeil, J., and Ouellette, M. (2009) *Nucleic Acids Res.* **37**, 1387–1399
63. Marquis, N., Gourbal, B., Rosen, B. P., Mukhopadhyay, R., and Ouellette, M. (2009) *Mol. Microbiol.* **57**, 1690–1699
64. Pérez-Pertejo, Y., Reguera, R. M., Ordóñez, D., and Baláñ-Foussé, R. (2006) *Biochim. Biophys. Acta* **1760**, 10–19
65. Landfear, S. M., Ullman, B., Carter, N. S., and Sanchez, M. A. (2004) *Eukaryot. Cell* **3**, 245–254